BioStem Technologies, Inc.BSEM
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · biostemtechnologies.com
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Key ratios
Operating cash flow growth
-82.0%TTM
2025
-59.4%
EPS growth
-0.4%TTM
FCF / Sales
13.9%2025
2024
34.5%2023
-21.6%
Net margin
-81.8%TTM
2025
-13.9%2024
44.6%2023
-50.8%
ROA
-18.1%TTM
2025
-0.8%2024
53.4%2023
-48.9%
ROE
-74.7%TTM
2025
-16.6%2024
160.5%
Revenue growth
-31.8%2025
2024
317.5%2023
142.7%
Track BSEM in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer